LEXX · Lexaria Bioscience Corp
United States · RS rating 91 · As of 2026-10-14
| Price | 2.82 USD |
|---|---|
| 1-day change | +0.7% |
| RS rating (overall / 1M / 3M / 12M) | 91 / 19 / 98 / 98 |
| Stage | Advancing |
| Composite / Minervini / CANSLIM score | 31 / 60 / 60 |
| Industry group (rank) | Medical-Ethical Drugs (91) |
| EPS growth Q/Q | +14.3% |
| Sales growth Q/Q | -100.0% |
| Distance from 52-week high | +80.1% |
| Market cap (USD) | $23.4M |